Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 24
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | ||
| NCT03926182 | Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers | ||
| NCT05009329 | A Study of JAB-21822 in Adult Patients with Advanced Solid Tumors Harboring KRAS P.G12C Mutation in China | ||
| NCT03452592 | Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M | ||
| NCT04895930 | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC | ||
| NCT03787992 | Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） | ||
| NCT03941340 | Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers | ||
| NCT04121286 | A Study of JAB-3312 in Adult Patients with Advanced Solid Tumors in China | ||
| NCT04858958 | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | ||
| NCT06162169 | A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects | ||
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | ||
| NCT06416410 | JAB-21822 Combined with JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer with KRAS P.G12C Mutation | ||
| NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer | ||
| NCT05194995 | JAB-21822 in Combination with Cetuximab in Patients with Advanced CRC and Other Solid Tumors with KRAS G12C Mutation | ||
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | ||
| NCT05920941 | Mass Balance Study of [14C]JAB-21822 | ||
| NCT03127449 | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | ||
| NCT05466149 | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion | ||
| NCT04853342 | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | ||
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | ||
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients with Pancreatic Cancer and Other Solid Tumors Harboring the KRAS P.G12C Mutation. | ||
| NCT05875493 | A Food Effect Study of JAB-21822 in Healthy Subjects | ||
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients with Advanced Solid Tumors Harboring KRAS P.G12C Mutation | ||
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
